S. Karger AG

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Rosenberg
    Rosenberg
  3. Feldman
    Feldman
  4. Iyer
    Iyer
  5. Scher
    Scher
  6. Abida
    Abida
  7. Bajorin
    Bajorin
  8. Bosl
    Bosl
  9. Busam
    Busam
  10. Chen
    Chen

Groups

  1. Department of Medicine (35)
  2. Genitourinary Oncology Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Survivorship Research (2)
  5. Breast Medicine Service (1)
  6. Center for Hematologic Malignancies (1)
  7. Department of Pathology and Laboratory Medicine (1)
  8. Dermatology Service (1)
  9. Dermatology (1)
  10. Division of Subspecialty Medicine (1)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (6)
  3. Book Section (1)
Groups
  1. Department of Medicine (35)
  2. Genitourinary Oncology Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Survivorship Research (2)
  5. Breast Medicine Service (1)
  6. Center for Hematologic Malignancies (1)

More Groups

People
  1. Robert Motzer (23)
  2. Jonathan Rosenberg (5)
  3. Darren Feldman (2)
  4. Dean Bajorin (2)
  5. Gopakumar Iyer (2)
  6. Howard Scher (2)

More People

Years
  1. 2022 (2)
  2. 2021 (4)
  3. 2020 (6)
  4. 2019 (3)
  5. 2018 (7)
  6. 2017 (2)

More Years

Publications
  1. Oncology Research and Treatment (27)
  2. Oncology (3)
  3. Onkologie (2)
  4. Basic Research in Urological Oncology (1)
  5. Case Reports in Oncology (1)
  6. Urologia Internationalis (1)

Results (35)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Gen für gen-analyse in der MAGNITUDE-studie mit niraparib (NIRA) und abirateronacetat plus prednison (AAP) bei patienten (pts) mit metastasiertem kastrationsresistentem prostatakarzinom (mCRPC) und homologen rekombinationsreparatur (HRR) genveränderungen
    Meeting Abstract

    Schlack, K.; Sandhu, S.; Attard, G.; Olmos, D.; Efstathiou, E.; Castro, E.; Rathkopf, D. E.; Smith, M. R.; Roubaud, G.; Small, E. J.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Entitäten-unabhängige sicherheit und wirksamkeit von erdafitinib bei patienten mit fortgeschrittenen soliden tumoren mit präspezifizierten genomischen fgfraberrationen (RAGNAR Interimanalyse)
    Meeting Abstract

    Schuler, M.; Loriot, Y.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso, G. T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Meeting Abstract

    Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Treatment of metastatic extramammary Paget disease with combination ipilimumab and nivolumab: A case report
    Journal Article

    Guercio, B. J.; Iyer, G.; Kidwai, W. Z.; Lacouture, M. E.; Ghafoor, S.; Rossi, A. M.; Assis, D. N.; Chen, Y. B.; Busam, K. J.; Janjigian, Y. Y.; more...
    Case Reports in Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bedke, J.; Merseburger, A. S.; Loriot, Y.; Castellano, D.; Choy, E.; Duran, I.; Rosenberg, J.; Petrylak, D. P.; Dreicer, R.; Perez-Gracia, J. L.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab (N+I) for treatment-refractory advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Loidl, W.; Choueiri, T. K.; Kluger, H.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Long-term follow-up on overall survival and independent review of response in CheckMate 214: First-line nivolumab plus ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Grimm, M. O.; Tannir, N.; McDermott, D.; Escudier, B.; Hammers, H.; Frontera, O. A.; Plimack, E.; Barthelemy, P.; Neiman, V.; George, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101
    Meeting Abstract

    Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B.I.; Schmidinger, M.; Larkin, J.; Haanen, J. B. A. G.; Kollmannsberger, C.; Campbell, M. T.; Pal, S. K.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save